دورية أكاديمية
Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma
| العنوان: | Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma |
|---|---|
| المؤلفون: | Puig, Noemí, Contreras, María Teresa, Agulló, Cristina, Martínez López, Joaquín, Oriol Bosch, Albert, Blanchard, María Jesús, Ríos, Rafael, Martín, Jesús, Iñigo, María Belén, Sureda, Anna, Hernández, Miguel Teodoro, De La Rubia, Javier, González Calle, Verónica, Krsnik, Isabel, Cabañas, Valentín, Palomera, Luis, Moraleda, José María, Bargay, Joan, Cedena, María Teresa, Paiva, Bruno, Rosiñol, Laura, Bladé, J. (Joan), San Miguel, Jesús, Lahuerta, Juan José, Mateos, María Victoria |
| المصدر: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
| بيانات النشر: | American Society of Hematology |
| سنة النشر: | 2022 |
| المجموعة: | Dipòsit Digital de la Universitat de Barcelona |
| مصطلحات موضوعية: | Anticossos monoclonals, Espectrometria de masses, Monoclonal antibodies |
| الوصف: | Monitoring of the monoclonal protein (M-protein) by electrophoresis and/or immunofixation (IFE) has long been used to assess treatment response in multiple myeloma (MM). However, with the use of highly effective therapies, the M-protein becomes frequently undetectable, and more sensitive methods had to be explored. We applied IFE and mass spectrometry (EXENT&FLC-MS) in serum samples from newly diagnosed MM patients enrolled in the PETHEMA/GEM2012MENOS65 obtained at baseline (n = 223), and after induction (n = 183), autologous stem cell transplantation (n = 173), and consolidation (n = 173). At baseline, the isotypes identified with both methods fully matched in 82.1% of samples; in the rest but 2 cases, EXENT&FLC-MS provided additional information to IFE with regards to the M-protein(s). Overall, the results of EXENT&FLC-MS and IFE were concordant in >80% of cases, being most discordances due to EXENT&FLC-MS+ but IFE cases. After consolidation, IFE was not able to discriminate 2 cohorts with different median progression-free survival (PFS), but EXENT&FLC-MS did so; furthermore, among IFE patients, EXENT&FLC-MS identified 2 groups with significantly different median PFS (P = .0008). In conclusion, compared with IFE, EXENT&FLC-MS is more sensitive to detect the M-protein of patients with MM, both at baseline and during treatment, and provides a more accurate prediction of patients' outcome. |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | 6 p.; application/pdf |
| اللغة: | English |
| تدمد: | 2473-9537 |
| العلاقة: | Reproducció del document publicat a: https://doi.org/10.1182/bloodadvances.2021006762Test; Blood Advances, 2022, vol. 6, núm. 11, p. 3234-3239; https://doi.org/10.1182/bloodadvances.2021006762Test; http://hdl.handle.net/2445/188952Test; 9298490 |
| الإتاحة: | https://doi.org/10.1182/bloodadvances.2021006762Test http://hdl.handle.net/2445/188952Test |
| حقوق: | cc by-nc-nd (c) Puig, Noemí et al., 2022 ; http://creativecommons.org/licenses/by-nc-nd/3.0/esTest/ ; info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.973F190F |
| قاعدة البيانات: | BASE |
Full Text Finder | تدمد: | 24739537 |
|---|